

# Viveca Ritsinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8801396/publications.pdf>

Version: 2024-02-01

14  
papers

295  
citations

1163117

8  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

589  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 627-633.	11.4	73
2	High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002328.	3.9	54
3	Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 23-32.	2.0	49
4	Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1890-1901.	1.8	24
5	Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities – A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 69-76.	2.0	19
6	Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 77-87.	2.0	19
7	Elevated admission glucose is common and associated with high short-term complication burden after acute myocardial infarction: Insights from the VALIDATE-SWEDEHEART study. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 582-584.	2.0	15
8	Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097367.	2.0	9
9	Characteristics and Prognosis in Women and Men With Type 1 Diabetes Undergoing Coronary Angiography: A Nationwide Registry Report. <i>Diabetes Care</i> , 2018, 41, 876-883.	8.6	8
10	Dynamics of testosterone levels in patients with newly detected glucose abnormalities and acute myocardial infarction. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 511-518.	2.0	7
11	Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 387-395.	2.0	6
12	Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study. <i>International Journal of Cardiology</i> , 2021, 330, 23-29.	1.7	6
13	Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes. <i>Journal of the American Heart Association</i> , 2021, 10, e022667.	3.7	6
14	Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort. <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	0